Legal Representation
Attorney
David S. Kerr
USPTO Deadlines
Next Deadline
2051 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2025-03-04)
Due Date
March 04, 2031
Grace Period Ends
September 04, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
13 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 4, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Mar 4, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Jan 14, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jan 14, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jan 8, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Dec 20, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Dec 20, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Dec 20, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Dec 20, 2024 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 20, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 19, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 14, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 14, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Research and development in the fields of pharmaceuticals, therapeutics, and biologics, namely, yeast derived extracellular vesicle-based delivery systems for pharmaceuticals, therapeutics, and biologics; Research and development in the fields of pharmaceuticals, therapeutics, and biologics, namely, development of humanized yeast extracellular vesicles delivery systems for pharmaceuticals, therapeutics, and biologics; Medical research and development in the field of molecular biology, genetic engineering, drug delivery, and bioinformatics; Medical research and development in the field of molecular biology, genetic engineering, drug delivery, and bioinformatics, namely genetically engineering yeast cells to produce extracellular vesicles for delivery of pharmaceuticals, therapeutics, and biologics; Bioinformatics, namely genetically engineering yeast cells to produce humanized extracellular vesicles delivery of for pharmaceuticals, therapeutics, and biologics; Research and development of delivery systems for therapeutic compounds, namely, yeast-derived extracellular vesicle-based drug delivery systems for therapeutic compounds for the treatment of viral pathogens, cancer and inherited disorder in humans; Research and development of delivery systems for therapeutic compounds, namely, yeast-derived extracellular vesicle-based drug delivery of therapeutic compounds; Research and development of delivery systems for therapeutic nucleic acids, namely, yeast-derived extracellular vesicle-based drug delivery of therapeutic nucleic acids, namely, RNA; Research and development of delivery systems for therapeutic peptides, namely, yeast-derived extracellular vesicle-based drug delivery of therapeutic peptides; Research and development of delivery systems for gene-editing proteins, namely, yeast-derived extracellular vesicle-based drug delivery of gene-editing proteins; Research and development of delivery systems for vaccines, namely, yeast-derived extracellular vesicle-based drug delivery systems for vaccines; Research and development of delivery systems for vaccines, namely, yeast-derived extracellular vesicle-based drug delivery systems for pharmaceutical compounds; Research and development of the production of extracellular vesicles for therapeutic uses, namely, yeast-derived extracellular vesicles for therapeutic uses; Research and development of new biological products for therapeutic use; Design and development of nucleic acids, proteins, enzymes, and drug compounds for use in pharmaceuticals, biotechnology, medical, and diagnostic applications; and Design and development of loading systems to load nucleic acids, proteins, enzymes, and drug compounds into yeast-derived extracellular vesicles for therapeutic uses
First Use Anywhere:
Jan 17, 2023
First Use in Commerce:
Jan 17, 2023
Classification
International Classes
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIO"